Showing results (1-10 of 559) with videos related to
Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2015
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysisDaniel A Goldstein, Qiushi Chen, Turgay Ayer, et al.Oncology (Williston Park, N.Y.)|March 19, 2015
Costs and effectiveness of genomic testing in the management of colorectal cancerDaniel A Goldstein, Walid L Shaib, Christopher R FlowersJAMA Oncology|August 28, 2015
Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based CostDaniel A Goldstein, Qiushi Chen, Turgay Ayer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal CancerDaniel A Goldstein, Bilal B Ahmad, Qiushi Chen, et al.Clinical Colorectal Cancer|October 13, 2014
Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancerDaniel A Goldstein, Qiushi Chen, Turgay Ayer, et al.Journal of Gastrointestinal Oncology|July 25, 2017
Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinomaSimon B Zeichner, Daniel A Goldstein, Christine Kohn, et al.The Annals of Thoracic Surgery|June 26, 2016
Successful Robotic Excision and Early Chemotherapy for Primary Cardiac LymphomaEmmanuel Moss, Daniel A Goldstein, Kyle T Bradley, et al.Clinical Colorectal Cancer|November 7, 2015
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current TherapiesDaniel A Goldstein, Simon B Zeichner, Catherine M Bartnik, et al.Leukemia & Lymphoma|October 26, 2017
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphomaQiushi Chen, Ashley D Staton, Turgay Ayer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced MelanomaChristine G Kohn, Simon B Zeichner, Qiushi Chen, et al.Pageof 56